MedTrace Logo

Esketamine and Butorphanol for Post-Lobectomy Pain

NCT06398834 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 223

Last updated 2024-05-06

No results posted yet for this study

Summary

Post-thoracotomy pain syndrome (PTPS) affects respiratory function, hindering sputum clearance and ventilation, and represents a significant complication of thoracic surgery. The analgesic effect of esketamine combined with butorphanol in PTPS is still unclear, so this study focused on this aspect.

Conditions

Interventions

DRUG

Esketamine

In the esketamine combined with butorphanol group (Group BK), patients received an intraoperative intravenous infusion of esketamine (0.3 mg/kg/h) followed by postoperative patient-controlled intravenous analgesia (PCIA) (esketamine 1.5 mg/kg + butorphanol 0.15 mg/kg + azasetron 20 mg).

DRUG

Butorphanol

In the butorphanol group (Group B), patients received an equivalent volume of normal saline intraoperatively and postoperatively received PCIA without esketamine.

Sponsors & Collaborators

  • Tongji Hospital

    collaborator OTHER

  • Second People's Hospital of Hefei City

    lead OTHER

Principal Investigators

  • Xianwen Hu, PhD · The Second Hospital of Anhui Medical University

  • Wensheng He, MD · The Second People's Hospital of Hefei

  • Xin Wang, MD · The Second People's Hospital of Hefei

  • Zicheng Wang, MD · The Second People's Hospital of Hefei

  • Junbao Zhang, MD · The Second People's Hospital of Hefei

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-03-01
Primary Completion
2023-10-01
Completion
2024-01-01

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06398834 on ClinicalTrials.gov